Patent ID: 11918622
Assignee: MAIA PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 15:
16. A method of inhibiting blood clots in a patient in need thereof comprising intravenously administering to the patient a therapeutically effective amount of a ready-to-use liquid composition comprising about 5 mg/mL (free base basis) of bivalirudin trifluoroacetate, about 0.8 mg/mL sodium acetate trihydrate, about 100 mg/mL PEG 400, and water, wherein
the composition is prepared by mixing the bivalirudin trifluoroacetate, sodium acetate, PEG 400, and water,
the composition is free of sodium chloride and dextrose,
the composition has a pH of from greater than 5.0 to 5.7, and
the percentage of total impurities increases by no more than about 9% from the time of manufacture of the composition up to 12 months of storage at 5° C. as determined by high performance liquid chromatography at a wavelength of 215 nm.